In light of the promising evidence regarding the beneficial effects of GLP-1 RAs in glycemic control and weight reduction, their use in diabetic and obese patients, respectively, has increased substantially
This shift is particularly relevant for procurement functions, which must balance cost efficiency with supply reliability in the face of increasing demand and constrained manufacturing capacity
A., Meier, J., Hucking, K
A large registry-based study from Denmark showing that people with IBD treated with GLP-1 RA had a lower risk of IBD-related adverse clinical events compared with those receiving other antidiabetics
Evidence suggests that GLP-1 signaling may mediate inflammatory pathways involved in some metabolic, pulmonary and neurologic disorders